Download MendeleyDiscovery of Galactopyranose-1-carboxamides as a New Class of Small, Novel, Potent, Selective, and Orally Active Galectin-3 Inhibitors.
Zumbrunn, C., Remen, L., Sager, C.P., Grisostomi, C., Stamm, C., Krusi, D., Glutz, S., Schmidt, G., Nayler, O., Iglarz, M., Mac Sweeney, A., Chambovey, A., Muller, M., Mueller, C., Bourquin, G., Meyer, S., Huhn, E., Cattaneo, C., Vercauteren, M., Gatfield, J., Bolli, M.H.(2025) ChemMedChem 20: e202401012-e202401012
- PubMed: 40071533
- DOI: https://doi.org/10.1002/cmdc.202401012
- Primary Citation of Related Structures:
8RMT, 8RMU, 8RMV, 9FDB, 9FDC - PubMed Abstract:
Galectin-3 (Gal-3), a β-galactoside-binding lectin, is implicated in diverse cellular functions ranging from immune response modulation to tissue homeostasis. Notably, increased Gal-3 expression has been linked to the progression of numerous diseases, including cancer, fibrosis, and cardiovascular disorders, underscoring its potential as a therapeutic target. Small molecule inhibitors have been discovered and are valuable tools to study such diseases. We report here the discovery of novel, galactose-based, small molecule inhibitors such as compound 12 which are orally bioavailable and show efficacy in a mouse model of acute liver injury and fibrosis (CCl 4 model). The use of structure-based drug design (docking of a virtual library of amides based on acid 2) was key in the process towards potent, nanomolar inhibitors.
- Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123, Allschwil, Switzerland.
Organizational Affiliation:
